Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36870451/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: PDS Q24W showed noninferior efficacy to monthly ranibizumab through approximately 2 years, with approximately 95% of PDS Q24W patients not receiving supplemental ranibizumab treatment in each refill-exchange interval. AEs were generally manageable, with learnings continually implemented to minimize PDS-related AEs.
Twenty-year outcome in neovascular age-related macular degeneration treated with photodynamic therapy and intravitreal bevacizumab/ranibizumab injections: a case report
Source : https://www.sciencedirect.com/science/article/abs/pii/S1572100023000777?via=ihub
A 64-year-old Chinese female with a history of hypertension presented with acute painless vision loss in the left eye in March 2002. Baseline diagnostic included visual acuity (VA) and intraocular...
Conclusions: When the patient came to our hospital for the first time in 2002, PDT was the only therapy available for nAMD. She showed a good response to the first PDT monotherapy and achieved a treatment interval of up to 9 years. PDT has been reported to prolong the anti-VEGF injection interval and/or reach a better treatment response....
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries - Ophthalmology and Therapy
Source : https://link.springer.com/article/10.1007/s40123-023-00672-6
Diabetic macular oedema (DMO) is the leading cause of vision loss associated with diabetic eye disease. The exponential increase in the diabetic population and thus, of DMO is an impetus...
Conclusions: Under both circumstances, this review aims to compare efficacy outcomes and adverse events of DMO therapies within the scope of anti-vascular endothelial growth factor (anti-VEGF) medications, specifically the commonly used ones—bevacizumab, ranibizumab and aflibercept.
CD11c+ macrophages are pro-angiogenic and necessary for experimental choroidal neovascularization - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36821388/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: These findings broaden our understanding of ocular macrophage heterogeneity and implicate CD11c macrophages as a potential therapeutic target for treatment-resistant nAMD patients.
Spontaneous Resolution of Subretinal Detachment in Choroidal Osteoma Unresponsive to Antivascular Endothelial Growth Factor Agent and Multimodal Imaging: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36796349/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The underlying mechanism behind the spontaneous resolution of SRD in this case is unclear. Vascular leakage and focal RPE leakage on the surface of the tumor likely led to the unresponsiveness of SRD to anti-VEGF therapy. Spontaneous regression of the SRD may have begun with the recovery of the blood-retina barrier and RPE. In a...